{
  "docId": "019de072-b09f-7797-83e5-c925df87e1b3",
  "docSlug": "fb96dc8e32131cd826524e728a742819",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 36 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 36,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 44,
  "notes": "Includes footnotes explaining context for hypertension and cytopenia events compared to standard chemotherapy agents.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-b09f-7797-83e5-c925df87e1b3/28",
  "deckHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3",
  "deckJsonHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3.json",
  "deckAnchorHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.11,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "*In clinical trials of bevacizumab, incidence of Grade 3-4 hypertension ranged between 5%-18% (Avastin label). It is typically managed by anti-hypertensive drugs. **Labeled Grade 3/4 cytopenia events for concomitant chemotherapy agent: Irinotecan: 31.4% neutropenia, 4.5% anemia, 1.7% thrombocytopenia Paclitaxel: 52% neutropenia, 16% anemia, 7% thrombocytopenia",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e378ee0a-bb05-46d0-83bd-27b4207558c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.63,
        "w": 0.78,
        "x": 0.11,
        "y": 0.215
      },
      "kind": "table",
      "text": "Drug-related adverse events observed in > 1 patient; Total (n); Total (%); Grade 3 (n); Grade 3 (%); Hypertension; 5; 29%; 4; 24%; Pulmonary hypertension; 5; 29%; 0; 0%; Neutropenia; 4; 24%; 3; 18%; Anemia; 3; 18%; 3; 18%; Thrombocytopenia; 2; 12%; 2; 12%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ac1888c-6b17-4c76-bc62-ee32bf965956",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.04,
        "y": 0.11
      },
      "kind": "title",
      "text": "Phase 1b Combination Safety Data",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e1854f5-8e0b-4dc7-ad0f-a3fa4ff40c87",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 36,
      "from": 25,
      "beatId": "c3e7dd54-708c-4a71-a4db-a7911d1931ca",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 25-36 present CTX-009 as a solution, showcasing its potential and clinical trial results.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 36,
      "from": 25,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "30be28e7-9f6a-4af1-9294-56a42dafdcd7",
      "evidence": "Slides 25-36 present CTX-009 as a promising solution, highlighting its potential for a quick win and big bet.",
      "position": 1,
      "objective": "Can CTX-009 provide a quick win and a big bet for BTC treatment?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}